LAVA Therapeutics
LVTX
LVTX was delisted on the 20th of November, 2025.
20 hedge funds and large institutions have $10.2M invested in LAVA Therapeutics in 2025 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 8 closing their positions.
361% more capital inflows, than outflows
Capital inflows: $2.26M | Capital outflows: $490K
5.98% more ownership
Funds ownership: 24.62% → 30.6% (+6%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
9% less funds holding
Funds holding: 22 → 20 (-2)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$2.18M |
| 2 |
XTX Topco
George Town,
Cayman Islands
|
+$27.1K |
| 3 |
LDNAM
Lepercq De Neuflize Asset Management
New York
|
+$25.6K |
| 4 |
Two Sigma Investments
New York
|
+$9.95K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$5.59K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Bruce & Co
Chicago,
Illinois
|
-$278K |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$86.7K |
| 3 |
Engineers Gate Manager
New York
|
-$30.4K |
| 4 |
DP
Diadema Partners
Morristown,
New Jersey
|
-$20.5K |
| 5 |
VF
Virtu Financial
New York
|
-$19K |
LVTX Hedge Fund Activity: Q1 2025 in Review
20 of the 7,478 institutional investors tracked by Wall St. Rank reported a position in LAVA Therapeutics (LVTX) for Q1 2025, worth a combined $10.2M — up 66% from $6.15M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of LVTX and 6 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 3 added.
The largest buyer was BML Capital Management, opening a new position worth an estimated $2.18M. The largest seller was Bruce & Co, cutting an estimated $278K.
- 20 institutional investors held LAVA Therapeutics (LVTX) as of Q1 2025, down from 22 in Q4 2024.
- Funds reported $10.2M of LAVA Therapeutics stock for Q1 2025, up 66% quarter-over-quarter.
- 6 funds opened new LAVA Therapeutics positions in Q1 2025 and 8 closed out, a net change of -2 holders.
- The largest LAVA Therapeutics buyer in Q1 2025 was BML Capital Management, an estimated $2.18M added.
- The largest LAVA Therapeutics seller in Q1 2025 was Bruce & Co, an estimated $278K sold.
Based on aggregated 13F filings for Q1 2025.